ABCL vs CRL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABCL and CRL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABCL and CRL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Since 2023 it has deliberately scaled back partnership volume to redirect resources into its own internal pipeline, marking a shift from a services-and-royalties model toward being a clinical-stage drug developer that captures more of the upside if its molecules succeed.

Full ABCL guide

Charles River Laboratories International, Inc. is a leading global contract research organization that helps pharmaceutical and biotech companies discover, develop, and safely test new drugs. It runs three reporting segments: Research Models and Services (RMS), which breeds and supplies purpose-bred lab animals and related services; Discovery and Safety Assessment (DSA), its largest segment, which runs toxicology and safety-testing studies that drugs must pass before human trials; and Manufacturing Solutions, which provides quality-control testing for biologics, cell and gene therapies, and other products. Charles River says it has supported a large majority of the drugs approved by the FDA in recent years, which underlines how embedded it is in the industry's R&D pipeline.

Full CRL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABCL drivers: Own-pipeline catalysts in 2026; Deep cash runway.
• CRL drivers: Biopharma R&D demand recovery; Activist-driven strategic review.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. For CRL, the central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending.

Pick ABCL if you believe its drivers more; CRL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABCL and CRL guides.

ABCL. AbCellera has no P/E because it is unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality: a large portion of the roughly $2.4B market value is backed by its cash and liquidity, with the remainder pricing the pipeline. Revenue is small and lumpy relative to the market cap, which is normal for a clinical-stage biotech but means the shares trade on catalysts, not fundamentals. Analyst views vary; for example Benchmark upgraded the stock to Buy with an $11 target, reflecting how much depends on the 2026 readouts.

CRL. All figures here are approximate and tied to the asOf date; verify live numbers on a current quote page or the latest SEC filing before acting. CRL is a services company, so its value depends on biopharma R&D demand, execution on cost savings, and the outcome of the strategic review, not on any single commodity price. Valuation multiples are more meaningful here than for a cyclical producer, but they still swing with where the demand cycle sits.

Headline figures (approximate, JULY 2026): ABCL shows market cap ~$2.4B, share price ~$7.70, revenue (q1 2026) ~$8.3M (up from ~$4.2M yr-ago), net loss (q1 2026) ~$43M; CRL shows revenue trend Roughly flat to slightly up recently, with quarterly revenue around the $1 billion mark; annual revenue in the multi-billion range. Figures are approximate, verify live., profitability Profitable on an adjusted basis; GAAP earnings have been pressured by soft DSA demand and restructuring, with a cost-savings program aimed at protecting margins., balance sheet Carries acquisition-related debt; management has prioritized deleveraging and disciplined capital allocation. Confirm current leverage on the latest filing., market cap tier Mid-cap. Approximate figure has been in the several-billion-dollar range, well below its historical peak. Verify the live number..

ABCL and CRL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABCL and CRL exposure against your real portfolio. It is not an investment adviser.